Ascend Gene & Cell Therapies
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Ascend Gene & Cell Therapies, founded in the UK in 2021 by Monograph Capital, is a specialist contract development and manufacturing organization (CDMO) for gene and cell therapies. It offers process development, GMP clinical manufacturing and analytical support, initially focused on high-quality adeno-associated virus (AAV) vectors, with production in Potters Bar near London, research in the San Francisco Bay Area and a team in Munich. It launched publicly in May 2023 with a $117.5 million Series A and renamed itself Ascend Advanced Therapies in March 2024.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Monograph Capital founds Ascend in the UK with $15 million in seed funding as a gene-therapy CDMO.
- Peak funding round
Ascend launches publicly in May 2023 with a $117.5 million Series A, acquiring Freeline Therapeutics' Munich manufacturing team.
- Product launch
The company renames itself Ascend Advanced Therapies in March 2024.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.